Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands, shares her insights on strategies currently being evaluated to improve the response to immunotherapy in triple-negative breast cancer (TNBC), including identifying biomarkers of response to immunotherapy, combination approaches with novel immune checkpoints as well as vaccines, bispecific antibodies and T-cell engagers. Dr. Kok provides a unique perspective on the challenges and opportunities of immunotherapy and highlights the latest approaches under evaluation to improve patient outcomes. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
